Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease
Identifieur interne : 000E19 ( Main/Exploration ); précédent : 000E18; suivant : 000E20Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease
Auteurs : W. R. Wayne Martin ; Marguerite Wieler ; A. Jon Stoessl [Canada] ; Michael Schulzer [Canada]Source :
- Annals of Neurology [ 0364-5134 ] ; 2008-03.
Abstract
Objective: To determine the sensitivity of positron emission tomography with11C‐labeled dihydrotetrabenazine (DTBZ) to the nigrostriatal changes associated with early, untreated Parkinson's disease (PD), and to determine the correlation between any regionally reduced DTBZ binding and the major motor features of PD. Methods: Untreated patients with early PD (n = 27) and age‐matched control subjects (n = 33) underwent DTBZ/positron emission tomography scanning to measure binding to the presynaptic type 2 vesicular monoamine transporter site in dopaminergic neurons in basal ganglia regions. Clinical symptoms were rated with the Unified Parkinson's Disease Rating Scale. Results: Mean striatal DTBZ binding values in the patient group were decreased as compared with control subjects (p < 0.001) in all regions examined. The difference between patients and control subjects was most marked in the midputamen, where only one patient had DTBZ binding within 3 standard deviations of the control mean. Bradykinesia and rigidity scores correlated with DTBZ binding in the contralateral midputamen region, particularly for the clinically least affected limbs. Tremor scores showed no significant correlation. Interpretation: Reduced striatal binding of DTBZ is associated with early PD. Tremor appears to be only partially related to presynaptic dopaminergic function and may have a mechanism differing from that of symptoms such as bradykinesia. The method appears to be most sensitive in mildly affected individuals with a possible “floor” effect that may limit the degree of additional change occurring once more severe clinical symptoms are evident. Ann Neurol 2008
Url:
DOI: 10.1002/ana.21320
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease</title><author><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W. R. Wayne" last="Martin">W. R. Wayne Martin</name></author><author><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:CDE87F5D8BB0927CF067801313B1DE34A6A4C63D</idno><date when="2008" year="2008">2008</date><idno type="doi">10.1002/ana.21320</idno><idno type="url">https://api.istex.fr/document/CDE87F5D8BB0927CF067801313B1DE34A6A4C63D/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">000380</idno><idno type="wicri:Area/Main/Curation">000327</idno><idno type="wicri:Area/Main/Exploration">000E19</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease</title><author><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W. R. Wayne" last="Martin">W. R. Wayne Martin</name><affiliation><wicri:noCountry code="subField">Alberta</wicri:noCountry></affiliation></author><author><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name><affiliation><wicri:noCountry code="subField">Alberta</wicri:noCountry></affiliation></author><author><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author><author><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name><affiliation wicri:level="1"><country xml:lang="fr">Canada</country><wicri:regionArea>Pacific Parkinson's Research Centre, University of British Columbia, Vancouver, British Columbia</wicri:regionArea><wicri:noRegion>British Columbia</wicri:noRegion></affiliation></author></analytic><monogr></monogr><series><title level="j">Annals of Neurology</title><title level="j" type="abbrev">Ann Neurol.</title><idno type="ISSN">0364-5134</idno><idno type="eISSN">1531-8249</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2008-03">2008-03</date><biblScope unit="volume">63</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="388">388</biblScope><biblScope unit="page" to="394">394</biblScope></imprint><idno type="ISSN">0364-5134</idno></series><idno type="istex">CDE87F5D8BB0927CF067801313B1DE34A6A4C63D</idno><idno type="DOI">10.1002/ana.21320</idno><idno type="ArticleID">ANA21320</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0364-5134</idno></seriesStmt></fileDesc><profileDesc><textClass></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Objective: To determine the sensitivity of positron emission tomography with11C‐labeled dihydrotetrabenazine (DTBZ) to the nigrostriatal changes associated with early, untreated Parkinson's disease (PD), and to determine the correlation between any regionally reduced DTBZ binding and the major motor features of PD. Methods: Untreated patients with early PD (n = 27) and age‐matched control subjects (n = 33) underwent DTBZ/positron emission tomography scanning to measure binding to the presynaptic type 2 vesicular monoamine transporter site in dopaminergic neurons in basal ganglia regions. Clinical symptoms were rated with the Unified Parkinson's Disease Rating Scale. Results: Mean striatal DTBZ binding values in the patient group were decreased as compared with control subjects (p < 0.001) in all regions examined. The difference between patients and control subjects was most marked in the midputamen, where only one patient had DTBZ binding within 3 standard deviations of the control mean. Bradykinesia and rigidity scores correlated with DTBZ binding in the contralateral midputamen region, particularly for the clinically least affected limbs. Tremor scores showed no significant correlation. Interpretation: Reduced striatal binding of DTBZ is associated with early PD. Tremor appears to be only partially related to presynaptic dopaminergic function and may have a mechanism differing from that of symptoms such as bradykinesia. The method appears to be most sensitive in mildly affected individuals with a possible “floor” effect that may limit the degree of additional change occurring once more severe clinical symptoms are evident. Ann Neurol 2008</div></front></TEI><affiliations><list><country><li>Canada</li></country></list><tree><noCountry><name sortKey="Martin, W R Wayne" sort="Martin, W R Wayne" uniqKey="Martin W" first="W. R. Wayne" last="Martin">W. R. Wayne Martin</name><name sortKey="Wieler, Marguerite" sort="Wieler, Marguerite" uniqKey="Wieler M" first="Marguerite" last="Wieler">Marguerite Wieler</name></noCountry><country name="Canada"><noRegion><name sortKey="Stoessl, A Jon" sort="Stoessl, A Jon" uniqKey="Stoessl A" first="A. Jon" last="Stoessl">A. Jon Stoessl</name></noRegion><name sortKey="Schulzer, Michael" sort="Schulzer, Michael" uniqKey="Schulzer M" first="Michael" last="Schulzer">Michael Schulzer</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000E19 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000E19 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:CDE87F5D8BB0927CF067801313B1DE34A6A4C63D
|texte= Dihydrotetrabenazine positron emission tomography imaging in early, untreated Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |